← Leaderboards
Adam Peter Mecca
University Of Florida
$5,618,285
Attributed
$5,618,285
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.2M · FY2008–23$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,618,285 · 3
By mechanism
R01$4,500,015 · 1
K23$977,376 · 1
F30$140,894 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- Annette Diane De Kloet$4,299,026
- Eric Gerald Krause$10,526,367
- Colin Sumners$12,690,977
- Weihong Tan$6,516,065
- Aaron David Mickle$3,047,112
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposIn VivoReceptorBaseInvestigationMolecularMediatingLigandsImpairmentInstitutionDisease ProgressionInnovationDesignGlycoproteinsBiological MarkersCognitive PerformanceClinical TrialsBindingDementiaDensityAmyloid Beta-ProteinBrainCognitionCoupled
Grant awards (12)
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's Disease$988,498
R01 · FY2023 · AG · contact PI
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's Disease$1,543,652
R01 · FY2022 · AG · contact PI
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.$195,393
K23 · FY2022 · AG · contact PI
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's Disease$1,967,865
R01 · FY2021 · AG · contact PI
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.$195,393
K23 · FY2021 · AG · contact PI
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.$195,530
K23 · FY2020 · AG · contact PI
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.$195,530
K23 · FY2019 · AG · contact PI
Investigation of molecular changes in mGluR5 and SV2A to study synaptic alterations in Alzheimer's disease using PET.$195,530
K23 · FY2018 · AG · contact PI
Cerebroprotection via viral-mediated gene delivery of angiotensin AT2 receptors$39,600
F30 · FY2011 · NS · contact PI
Cerebroprotection via viral-mediated gene delivery of angiotensin AT2 receptors$39,180
F30 · FY2010 · NS · contact PI
Cerebroprotection via viral-mediated gene delivery of angiotensin AT2 receptors$31,159
F30 · FY2009 · NS · contact PI
Cerebroprotection via viral-mediated gene delivery of angiotensin AT2 receptors$30,955
F30 · FY2008 · NS · contact PI